Cat# : VLP-354
| Catalog# | Product Name | Availability | Size | Price | Qty |
|---|---|---|---|---|---|
| VLP-354 | TG4010 | April 27, 2024 | 1 vial | $998.00 |
|
| Add to Cart Online Order Request a Bulk Order | |||||
| Cat#: | VLP-354 |
| Product Name: | TG4010 |
| Description: | A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. 1 |
| Cas No: | 350485-85-7 |
| Biologic Classification: | Vaccines Other Vaccines |
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © 2024 Creative BioMart. All Rights Reserved.
